Olvi-Vec plus chemotherapy for advanced small cell lung cancer
Part of Cancer clinical trials.
This trial tests a new drug called Olvi-Vec combined with standard chemotherapy (platinum plus etoposide) for people with advanced small cell lung cancer that has already been treated and is no longer responding. The goal is to see if this combination can help shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have small cell lung cancer (confirmed by a biopsy or cell test).
- Your cancer has gotten worse or come back after at least one type of standard treatment (like chemotherapy, immunotherapy, or anlotinib).
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are in good physical shape (ECOG score 0 or 1) and your main organs (bone marrow, liver, kidneys) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a new combination of two drugs (YL201 and serplulimab) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the combination helps shrink or control the cancer.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial tests whether a combination of two immunotherapy drugs (toripalimab and JS004) plus chemotherapy can help control relapsed or extensive-stage small cell lung cancer. It is designed for people whose cancer has spread or returned and who are generally healthy enough to receive strong treatment.
This trial tests a combination of four drugs as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and effective. It may be an option for those who have not had prior treatment for advanced disease.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.